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Abstract
Objective: Several studies have reported the existence of a subgroup of obese individuals with normal metabolic profiles. It
remains unclear what factors are responsible for this phenomenon. We proposed that adipocyte size might be a key factor
in the protection of metabolically healthy obese (MHO) individuals from the adverse effects of obesity.
Subjects: Thirty-five patients undergoing bariatric surgery were classified as MHO (n=15) or metabolically unhealthy obese
(MUO, n=20) according to cut-off points adapted from the International Diabetes Federation definition of the metabolic
syndrome. Median body mass index (BMI) was 48 (range 40–71).
Results: There was a moderate correlation between omental adipocyte size and subcutaneous adipocyte size (r=0.59,
p,0.05). The MHO group had significantly lower mean omental adipocyte size (80.9610.9 mm) when compared with
metabolically unhealthy patients (100.067.6 mm, p,0.0001). Mean subcutaneous adipocyte size was similar between the
two groups (104.168.5 mm versus 107.967.1 mm). Omental, but not subcutaneous adipocyte size, correlated with the
degree of insulin resistance as measured by HOMA-IR (r=0.73, p,0.0005), as well as other metabolic parameters including
triglyceride/HDL-cholesterol ratio and HbA1c. Twenty-eight patients consented to liver biopsy. Of these, 46% had
steatohepatitis and fibrosis. Fifty percent (including all the MHO patients) had steatosis only. Both omental and
subcutaneous adipocyte size were significantly associated with the degree of steatosis (r=0.66, p,0.0001 and r=0.63,
p,0.005 respectively). However, only omental adipocyte size was an independent predictor of the presence or absence of
fibrosis.
Conclusion: Metabolically healthy individuals are a distinct subgroup of the severely obese. Both subcutaneous and
omental adipocyte size correlated positively with the degree of fatty liver, but only omental adipocyte size was related to
metabolic health, and possibly progression from hepatic steatosis to fibrosis.
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Introduction
The prevalence of chronic conditions such as type 2 diabetes,
hypertension and nonalcoholic fatty liver disease (NAFLD) increases
with increasing weight. However, not all obese individuals display
the expected features of metabolic dysfunction. Up to 30% of obese
individuals are metabolically healthy, and therefore may be
protected from the increased morbidity and mortality associated
with excess weight[1,2,3]. Several papers support the concept of
metabolically healthy obese (MHO) individuals and investigate what
factors characterize this phenotype[3,4,5,6]. Stefan et al reported
that individuals with ‘benign obesity’ demonstrated a higher degree
of insulin sensitivity, lower levels of ectopic fat in liver and skeletal
muscle, as well as lower carotid artery intima-media thickness, when
compared with an insulin resistant obese group. However, waist
circumference and degree of visceral adiposity were similar between
the two groups[5].
Adipose tissue is now firmly established as an endocrine organ,
producing a variety of important steroids, cytokines and
adipokines[7,8]. The adipocyte is therefore an obvious potential
determinant of the local and systemic metabolic environment.
Over 4 decades ago, adipocyte size was shown to vary inversely
with adipocyte insulin sensitivity[9]. More recently, studies have
shown functional differences in large and small adipocytes from
the same subjects, including altered gene expression profiles[10]
and a blunting of GLUT-4 translocation in response to insulin
stimulation in larger adipocytes[11]. Adipocyte size has also been
shown to influence adipokine secretion, with increasing adipocyte
size resulting in a shift towards dominance of pro-inflammatory
adipokines[12].
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e9997In general, metabolic disorders are associated more strongly
with visceral adiposity, rather than with subcutaneous adiposity.
Depot-related differences exist in adipocyte responses to lipolytic
and lipogenic stimuli, in adipocyte apoptosis, expression of
adipokine receptors, and secretion of adipokines[13,14,15,16].
Also, the anatomic location of visceral adipose tissue means that
fatty acids are released directly into the portal circulation and fat
accumulation in the liver has been shown to be an important
feature of the metabolic syndrome[17,18].
Few studies have focused on individuals with a body mass index
(BMI) .40, the fastest growing category of obesity[19]. The aim of
this study therefore, was to determine if adipocyte size is one of the
factors associated with the MHO phenotype in severe obesity. We
also investigated the relationship between adipocyte size and the
degree of NAFLD in these subjects.
Methods
Ethics statement
St Vincent’s University Hospital Ethics Committee approved
this study. Written informed consent was obtained from every
participant prior to the start of any research activities.
Subjects
We studied 48 consecutive, severely obese patients undergoing
bariatric surgery. All patients were attending the weight manage-
ment service for at least 1 year prior to surgery. They were weighed
monthly during this time. Patients were excluded from the study if
they had significant weight loss in the preceding 6 months (n=4),o r
if they were taking medications that could affect metabolic and/or
hepatic parameters (n=9). We obtained blood and omental adipose
tissue samples from the remaining 35 subjects. Nineteen of the 35
subjects consented to subcutaneous adipose tissue sampling. With
regard to age, BMI, and metabolic parameters, there was no
significant difference between the group who consented to biopsy
and those who did not. Mean age was 4267 years, median weight
was 150 kgs (range 103–240), and median BMI was 48 kgm
22
(range 40–71). There were 10 males and 25 females. Fifteen patients
were classified as metabolically healthy obese, based on their
metabolic profile, as detailed below. Six of the remaining 20
unhealthy patients had type 2 diabetes (DM2).
Defining metabolically healthy obese subjects
Metabolically healthy obese (MHO) subjects had no history of
cardiovascular, respiratory or metabolic diseases. They were not on
any lipid-lowering, anti-hypertensive, or hypoglycemic agents. Clinical
examination was unremarkable and thyroid status was normal.
Fasting glucose level was #5.6 mmol/L, blood pressure was #135/
85, and TGL/HDL cholesterol ratio was #1.65 (men) or #1.32
(women). These cut-off points were adapted from the International
Diabetes Federation worldwide consensus definition of the metabolic
syndrome, 2006. The plasma triglyceride/high-density lipoprotein
cholesterol concentration ratio was used as this has been shown to
provide a simple means of identifying insulin-resistant, dyslipidemic
patients who are likely to be at increased risk of cardiovascular
disease[20]. Metabolically unhealthy obese (MUO) subjects were
defined by failure to meet at least one of the criteria above.
Adipose tissue samples and determination of adipocyte
size
Approximately 10–30 gms of omental adipose tissue, or 5–
10 gms of abdominal subcutaneous adipose tissue, was obtained at
the time of bariatric surgery. A piece of this tissue was immediately
fixed in formalin, prior to paraffin mounting and preparation of
H&E slides. The remaining tissue was placed in warm DMEM-F12
medium, supplemented with 10%FCS, transported to the lab, and
processed within 1 hour. Adipocyte size was assessed by 2 methods.
Method I (n=35): Digital photomicrographs of H&E slides
were analyzed using UTHSCA Image Tool Software (University
of Texas Health Science Center). Two individual operators
calculated the maximal diameter of 100 adjacent adipocytes from
each of 4 separate photographs. This data was transferred to an
Excel program to calculate the mean adipocyte diameter and
standard deviation for each sample. Both operators were blinded
to patients’ clinical details.
Method II (n=10): Fresh samples of adipose tissue were
incubated in collagenase and DMEM-F12 medium (1 mg/ml
collagenase type II (Sigma C-6885)) for 60 minutes in a metabolic
shaker (60–80 strokes/min) at 37uC. The cell suspension was
filtered through a 250 mm Nitex mesh and washed 3 times in warm
medium - cells were allowed to float by gravity and the infranatant
removed using a syringe and 18 g needle, prior to adding fresh
medium, gently inverting the container each time to ensure an
even suspension. A 50 mL aliquot of the cell fraction (suspended in
medium) was diluted with 100 mL medium and 50 mL trypan blue
(0.4% in H2O). Ten mL of this solution was transferred to a
Neubauer chamber, digital photographs taken, and measurements
of mean adipocyte diameter calculated as above.
In order to ensure reproducibility of both methods, 2 operators
performed the analysis twice. The inter-individual correlation was
calculated to compare the results obtained by both individuals. The
intra-individual correlation was calculated to compare the results
obtained by the same individual repeating the measurements twice.
Liver biopsies and determination of the degree of fatty
liver
Liver biopsies were performed by the surgeon peri-operatively,
using a ‘Tru-Cut’ needle and immediately fixed in formalin.
Biopsy fragments were at least 10 mm, and contained at least 8
portal triads, in order to ensure accurate histological assessment.
Liver tissue was paraffin-embedded, stained with hematoxylin-
eosin, and with a standard panel of special stains (PAS +/2
diastase, iron, trichrome, reticulin and shikata).
The sections were then examined by a pathologist blinded to the
clinical details and the type and degree of steatosis reported. An
eyepiece graticule with a 100-point grid was inserted in the
eyepiece and the biopsy was viewed using the 10x objective. The
number of hits on fatty hepatocytes and normal hepatocytes was
counted; the process was repeated four times in each case. The
results are given as the percentage of biopsy area with fat
deposition. A diagnosis of steatohepatitis was made if there was
ballooning degeneration with Mallory’s hyaline, neutrophilic
infiltration and perisinusoidal or pericellular fibrosis[21]. Fibrosis
was assessed with the aid of the connective tissue stains trichrome
and shikata and classified as to its anatomical distribution and
stage: perisinusoidal and pericellular fibrosis, portal, periportal
fibrosis, septal, bridging fibrosis or cirrhosis.
Statistical Analyses
Data in the text and tables are presented as mean +/2 standard
deviation, or median, with the range in parentheses, as
appropriate. Student’s unpaired t-test or Mann-Whitney U tests
were used to test for differences between healthy and unhealthy
groups, and groups with and without hepatic fibrosis, as
appropriate. One-way analysis of variance (ANOVA) was used
to test for differences between healthy, unhealthy and DM2
groups. Post-hoc comparisons were assessed by Tukey HSD test.
Adipocyte Size in MHO
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adipocyte size were visualized by scatter plots and assessed by
Spearman rank correlation test (Spearman’s rho or r). Overall
correlation results were confirmed by subset correlation analysis of
the MHO and MUO groups to ensure that arrangement of the
groups did not artificially increase the correlation coefficient.
Scatter plots did not demonstrate distinct data groups. Direct
logistic regression was performed to assess the impact of a number
of factors on the likelihood of hepatic fibrosis.
P values ,0.05 were considered to be statistically significant.
When multiple analyses were performed on data sets, a Bonferroni
correction was used to set a higher alpha level.
Results
Measurement of adipocyte size
There was good agreement between methods I and II (Figure 1),
although the average cell diameter determined by Method I was
smaller than that obtained by Method II by a factor of
approximately 1.2. Intra-individual and inter-individual results
had correlation coefficients of 0.92 and 0.89, respectively. Further
analyses used measurements obtained by Method I.
Metabolic profile of healthy and unhealthy groups
Table 1 summarizes the clinical features of the MHO and the
MUO group. A smaller group with type 2 diabetes (DM2) was
considered separately to the MUO group. This group was slightly
older than the other groups, and predominantly female. The
MHO and MUO groups were matched for age, BMI, and gender
ratio. By design, the groups were significantly different with regard
to blood pressure, fasting blood glucose levels, and lipid profile.
Adipocyte size and metabolic status
Subcutaneous adipocytes were always larger than omental
adipocytes, with a moderate association seen between paired
samples (r=0.59, p,0.01). Mean omental adipocyte size was
91.8613.2 mm, mean subcutaneous adipocyte size was 106.46
7.6 mm. Gender did not appear to influence mean omental
adipocyte size (male: 92.5616.6 mm, female: 91.6611.9 mm;
p=0.81), however subcutaneous adipocyte size showed a trend
towards a higher mean value in men (male: 110.764.2 mm,
female: 104.467.9 mm; p=0.07). Neither omental nor subcuta-
neous adipocyte size showed any correlation with age or body
mass index.
The MHO group had a significantly lower mean omental
adipocyte size (80.9610.9 mm) when compared with the MUO
group (100.067.6 mm, p,0.0001). The unhealthy patients with
DM2 appeared to have a slightly larger adipocyte size when
compared to the unhealthy group without DM2, but this did not
reach statistical significance (104.364.2 mm and 98.268.2 respec-
tively, p=0.10). Subcutaneous adipocyte size was similar in both
healthy and unhealthy groups. (Figure 2)
Omental adipocyte size was shown to correlate strongly with the
degree of insulin resistance as measured by HOMA-IR (r=0.73,
p,0.0005), as well as other metabolic parameters, particularly
triglyceride level (r=0.65, p,0.0005), TGL/HDL ratio (r=0.67,
p,0.0005) and HbA1c (r=0.50, p,0.005). Subcutaneous adipo-
cyte size showed no correlation with any of these metabolic
parameters. (Figure 3)
Body mass index was associated with systolic blood pressure
(r=0.54, p,0.005), but there was no association with other
metabolic parameters.
Nonalcoholic fatty liver disease (NAFLD) in patients with
BMI.40
Twenty-eight of the 35 patients consented to an intra-operative
liver biopsy. Of these 28 biopsies, one biopsy was classified as
normal (from a MHO subject). Fourteen subjects (50%) had
evidence of steatosis only. Thirteen subjects (46%) had evidence of
nonalcoholic steatohepatitis (NASH) and varying degrees of fibrosis.
None of the MHO patients had evidence of NASH or fibrosis.
The degree of steatosis present showed a linear trend across
metabolic groups. The MHO group had the lowest median degree
of steatosis [3 (0–56%)]. The MUO group without DM2 had an
intermediate degree of steatosis [47.3 (3–70%)], between the MHO
and the group with DM2 [74 (32–98%)]; p,0.005). (Table 1)
Adipocyte size and NAFLD
Omental and subcutaneous adipocyte size showed strong
correlations with the degree of hepatic steatosis (omental:
r=0.66, p,0.0005, subcutaneous: r=0.63, p,0.05). (Figure 3)
The mean adipocyte size of the patients with evidence of hepatic
fibrosis was 100.667.2 mm (om) and 109.6.067.2 mm (sc),
Figure 1. Adipocyte size results (micrometers) for Method I and Method II.
doi:10.1371/journal.pone.0009997.g001
Adipocyte Size in MHO
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normal/fatty livers only [89.0611.1 mm (om) and 102.466.2 mm
(sc); p,0.005 (om), p,0.05 (sc)] as seen in Figure 4.
Age, body mass index, blood pressure and liver function tests
did not differ significantly between the two groups. With regard to
metabolic parameters, the group with hepatic fibrosis had trends
Table 1. Metabolically healthy obese (MHO) compared to metabolically unhealthy obese (MUO) and metabolically unhealthy
obese with type 2 diabetes (DM2).
MHO (n=15) MUO (n=14) DM2 (n=6) p value
Anthropometric and metabolic profile
M = /FR 5/10 4/10 1/5
Age 40 (23–52) 42 (33–56) 46 (38–53) ns
BMI (kgs/m2) 48 (40–59) 51 (44–71) 50 (40–55) ns
Systolic BP (mmHg) 119 (100–135) 132 (105–160) 137 (130–172) ,0.05
Diastolic BP (mmHg) 76 (50–85) 81 (62–105) 83 (70–95) ns
Fasting Glucose (mmol/L) 4.9 (4.2–5.4) 5.3 (4.1–6.0) 7.6 (7.2–12.2) ,0.0005
HbA1c (%) 5.4 (4.8–5.6) 5.6 (5.2–6.2) 7.4 (5.1–10.1) ,0.05
Cholesterol (mmol/L) 4.9 (3.1–5.7) 5.7 (4–7.2) 4.9 (4–8.1) ns
Triglyceride (mmol/L) 1.2 (0.7–1.7) 1.9 (1.3–3.2) 2.1 (1.6–6.1) ,0.0005
HDL (mmol/L) 1.3 (0.9–1.8) 1.2 (0.8–1.5) 0.9 (0.8–1.7) ns
TGL/HDL ratio 0.9 (0.5–1.5) 1.6 (1.0–3.7) 2.5 (0.9–5.8) ,0.0005
Fasting Insulin (mU/mL) 13.8 (6.7–17) 24.8 (12.9–42.2) ,0.05
HOMA-IR 1.7 (0.9–2.0) 3.0 (1.6–5.6) ,0.05
Adipocyte size (mm)
Omental n=35
10 = - 92.5 (16.6)
25 R - 91.6 (11.9)
80.9 (10.9) 98.2 (10.2) 104.3 (4.2) ,0.0001
Subcutaneous n=19
6 = - 110.7 (4.2)
13 R - 104.4 (7.9)
104.1 (8.5)
(3 =,4R)
104.9 (5.0)
(2 =,6R)
113.2 (6.9)
(1 =,3R)
ns
Liver biopsy results
Normal or steatosis only 9 of 9 5 of 14 1 of 5
NASH and/or fibrosis None 9 of 14 4 of 5
Degree of steatosis (%) 3 (0–56) 47 (3–70) 74 (32–98) ,0.005
Values are expressed as median and range in parentheses, except for adipocyte size, expressed as mean +/2 standard deviation in parentheses.
doi:10.1371/journal.pone.0009997.t001
Figure 2. Adipocyte size in obese subjects grouped by metabolic profile. Metabolically healthy obese = MHO, metabolically unhealthy
obese = MUO, metabolically unhealthy obese patients with Type 2 Diabetes = DM2. Mean omental adipocyte diameter (represented by the
horizontal lines) was 80.9610.9 mm in MHO, 98.2610.2 mm in MUO, and 104.3+/24.2 mm in DM2. Mean subcutaneous diameter was 104.168.5 mmi n
MHO, 104.965.0 mm in MUO, and 113.266.9 mm in DM2.
doi:10.1371/journal.pone.0009997.g002
Adipocyte Size in MHO
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IR, as well as a higher median degree of steatosis, when compared
with the normal/fatty liver only group (Figure 4). However, after
adjustment for multiple analyses, omental adipocyte size was the
only parameter that remained significantly higher in the group
with hepatic fibrosis.
Direct logistic regression was performed to assess the impact of a
number of factors on the likelihood of hepatic fibrosis being
present. The model included the independent variables age, sex,
BMI, degree of steatosis, omental adipocyte size, triglyceride to
HDL-cholesterol ratio (TGL/HDL-C) and fasting glucose [x
2 (7,
n=46)=20.4, p,0.005]. Only adipocyte size made a unique
statistically significant contribution to the model.
Discussion
We have shown that severely obese patients with healthy
metabolic profiles have significantly smaller omental adipocytes
Figure 3. Correlations of adipocyte size with metabolic parameters. Omental adipocyte size (A, B and C) and subcutaneous adipocyte size
(D, E and F) correlated with the degree of insulin resistance as measured by HOMA-IR, the TGL/HDL ratio, and the degree of hepatic steatosis. X =
MHO,N= MUO, #= DM2
doi:10.1371/journal.pone.0009997.g003
Adipocyte Size in MHO
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Furthermore, omental adipocyte size strongly correlated with the
degree of insulin resistance and the degree of hepatic steatosis.
Obese individuals with smaller adipocytes had no evidence of
hepatic fibrosis. Subcutaneous adipocyte size was significantly
associated with the degree of fat in the liver, but had no association
with metabolic parameters, and did not predict presence or
absence of hepatic fibrosis. Body mass index was not associated
with adipocyte size, and was also a poor indicator of metabolic
health or degree of fatty liver disease in this patient group (median
BMI 48).
Other studies have investigated the factors responsible for
protecting MHO individuals from developing co-morbidities such
as diabetes and dyslipidemia[4,5,6]. Body fat distribution is
thought to play a role in influencing the metabolic environment.
One study reported that lower amounts of visceral adipose tissue
explained 22% of the variance in insulin sensitivity between MHO
and MUO groups[4]. However, it has also been shown that while
the amount of visceral fat is a strong predictor of insulin resistance
in normal or overweight individuals, the predictive effect of
visceral fat mass is relatively weak in obese patients[5]. Obese
patients all have a significant degree of visceral adiposity. In this
patient group, the size of the omental adipocytes may be more
important than the size of the omental fat depot.
The overflow hypothesis proposes that as the size of an
adipocyte increases, it will eventually reach a limit and be unable
to store further lipid. Excess fatty acids then ‘overflow’ to ectopic
sites, including muscle and liver, leading to peripheral and hepatic
insulin resistance, respectively[22,23]. The results of our study
support this theory, suggesting that lipid overflow from hypertro-
phied subcutaneous fat cells accumulates in the omentum and
liver. Subsequent omental fat cell hypertrophy leads to more
detrimental metabolic effects, possibly because of close proximity
to hepatic and visceral immune cell populations.
In vitro work has shown that increasing adipocyte size varies
inversely with adipocyte insulin sensitivity[9]. Large adipocytes are
more likely to produce pro-inflammatory adipokines[12] and to
demonstrate increased basal and catecholamine-stimulated lipol-
ysis[24]. Large adipocytes also have altered gene expression
profiles when compared with smaller adipocytes[10]. These
studies have focused on subcutaneous adipocytes. However,
increased production of pro-inflammatory cytokines and other
adverse qualities of fat cells in vitro, may not translate to adverse
outcomes in vivo. Our study suggests that adipocyte size, in
severely obese individuals, is a strong indicator of metabolic
health, particularly when studying adipocytes from the omental
depot.
Subcutaneous adipocytes may not have a direct impact on
metabolic dysfunction, but they still may play a key role as the
initiating factor in the process of fat overflow to ectopic sites. Lonn
M et al showed that abdominal subcutaneous adipocyte size
predicted the onset of DM2 independently of body fat percentage
or waist to hip ratio in a Swedish cohort of women[25]. This work
confirmed the original finding by Weyer C et al in Pima
Indians[26]. The primary defect may be an inability of
subcutaneous adipose tissue proliferation and differentia-
tion[27,28]. In the setting of caloric excess, it may be that some
individuals have ‘healthier’ subcutaneous fat, capable of significant
hyperplastic expansion, and consequently a lesser degree of fat
overflow and omental adipocyte hypertrophy. The degree to
which subcutaneous and omental fat can expand to accommodate
excess calories may be highly variable across individuals and
degrees of body fat, perhaps determined by genetic, intrauterine or
environmental influences later in life.
In the setting of extremely obese individuals, as in our cohort,
the subcutaneous adipocytes may all have reached their maximum
expansion limit, and therefore MHO and MUO have similar
mean adipocyte size. However, MHO may have increased pre-
adipocyte and adipocyte number, and therefore overall greater
subcutaneous storage capacity. This would explain the smaller
omental adipocyte size, and consequent metabolic benefits, seen in
this group. Arner et al recently showed that total subcutaneous
adipocyte number was greatest in pronounced hyperplasia and
smallest in pronounced hypertrophy[29]. The mean BMI in this
study was 33 kg/m
2 so this association may be blunted at more
extreme levels of obesity (the mean BMI of our cohort was 50
kg/m
2).
We have studied abdominal subcutaneous fat in severely obese
subjects. Previous work has demonstrated morphological and
metabolic differences between abdominal, gluteal and femoral
subcutaneous adipose tissue depots[30,31,32]. However, increas-
ing body fat can also influence these differences. In one such study,
adipocyte size was shown to vary across the abdominal, gluteal
and femoral depots at normal and overweight BMI’s. Obese
individuals had similar adipocyte size at all 3 depots[31]. Lower
body subcutaneous fat may have a beneficial influence on
metabolic health but this influence may vary between normal
weight, overweight and obese individuals. Further research,
comparing the phenotypic and metabolic features of different
subcutaneous fat depots in metabolically healthy and unhealthy
obese individuals, would help to clarify the importance of
subcutaneous fat in metabolic disease. Intra-peritoneal visceral
fat can also be subdivided into omental and mesenteric fat[33],
with emerging evidence that mesenteric adipose tissue has a
distinct role in the insulin resistance of diabetes and the metabolic
syndrome[34,35,36].
Our study focuses on subjects with a median BMI of 48 kg/m
2
(mean BMI 50), a group lying at the extreme end of the obesity
spectrum. The associations between subcutaneous and omental
adipocyte size and metabolic parameters may vary in normal or
overweight individuals. This could account for the differences
between our findings, and those of other studies reporting
associations between subcutaneous adipocyte size and metabolic
risk, where the mean BMI of populations studied is usually 25–
30 kg/m
2 [31,37]. Another limitation of our study is that only
nineteen of the 35 subjects agreed to a subcutaneous fat biopsy.
However, correlation analysis of these 19 subjects alone (who all
underwent liver biopsy) confirms the results reported for the whole
group. Also, if we had greater numbers in our study, it would have
been preferable to analyse males and females separately. In order
to minimize gender influences we aimed to have a similar gender
ratio across the different groups (MHO and MUO have similar
gender ratios, DM2 has more females). Differences in fat cell size
between males and females have been shown to be more
prominent in peripheral subcutaneous fat sites[30]. The relation-
ship between fat cell size and lipoprotein lipase activity is similar in
males and females in abdominal fat but not gluteal fat[30]. Lastly,
catecholamine mediated leg free fatty acid release is lower in
Figure 4. Omental adipocyte size, metabolic parameters and hepatic fibrosis. A) Omental and subcutaneous adipocyte size, B) TGL/HDL
and HOMA-IR ratios and C) Age, BMI and degree of steatosis, in subjects with hepatic steatosis alone, compared with subjects with evidence of
hepatic fibrosis (** p,0.005). The data are presented as median values and inter-quartile range.
doi:10.1371/journal.pone.0009997.g004
Adipocyte Size in MHO
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body depots is comparable[38]. In summary, gender-related
differences appear to be less pronounced in abdominal subcuta-
neous fat depots.
NAFLD has been described as an additional feature of the
metabolic syndrome and there is a strong link between NAFLD
and obesity. However, similar to other parameters of metabolic
health, not all obese individuals develop NAFLD. In the setting of
severe obesity, the prevalence of NAFLD ranges from 75–
85%[39]. Within our cohort, 96% of patients had NAFLD and,
48% of those patients had evidence of steatohepatitis and fibrosis.
Predicting which patient will progress from steatosis to fibrosis is
difficult, even with information provided by liver biopsy. Recent
studies indicate that the histological severity of NAFLD correlates
with the indices of the metabolic syndrome, particularly degree of
insulin resistance[40,41]. We have shown that obese individuals
with larger adipocytes are more likely to develop steatosis. Those
with larger omental adipocytes are more likely to progress to
hepatic fibrosis. This may be secondary to the association of
increased adipocyte size and insulin resistance. However, larger
adipocytes are positively correlated with adipose tissue macro-
phage number and production of pro-inflammatory cytokines
TNF-a and IL-6 in mice[42]. Omental macrophage accumulation
is also associated with the severity of fibroinflammatory liver
damage, independently of degree of insulin resistance[43,44]. In
addition, adipocyte volume was found to have a significant positive
correlation with serum TNF-a levels and soluble TNF receptors in
lean and overweight patients[45]. Finally, secretion of the pro-
inflammatory adipocytokines leptin, IL-6, IL-8, and monocyte
chemoattractant protein-1 from cultured adipocytes correlated
positively with cell size[12]. It may be that increased omental
adipocyte size is also playing a key role in the ‘second hit’ of the
‘two hit’ hypothesis for steatohepatitis[46]. Increased pro-inflam-
matory adipocytokine production, from hypertrophied omental
adipocytes and associated macrophages, may lead to a higher
likelihood of progression to fibrosis from simple fatty liver.
In summary, we demonstrate a relationship between omental
and subcutaneous adipocyte size and the degree of hepatic
steatosis, in the severely obese. Omental, but not subcutaneous,
adipocyte size was also associated with metabolic health and
presence of hepatic fibrosis. Whether this relationship is causal,
perhaps in part via the overflow hypothesis, remains to be
elucidated. Our data support the concept of the metabolically
healthy subgroup within the severely obese population, and
suggest that the size of the individual’s adipocytes is more
important than the size of the individual.
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